Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey.

BACKGROUND

Being familiar with the care of patients with breast cancer who are receiving abemaciclib, including adverse event (AE) management, supports care.

OBJECTIVES

This article describes the care of patients with breast cancer receiving abemaciclib, including AE data from clinical trials and nonpharmacologic interventions in real-world practice through a survey of healthcare providers.

METHODS

Safety data from the monarchE, MONARCH 1, MONARCH 2, and MONARCH 3 trials were reviewed. A quantitative survey of advanced practitioners, oncologists, and pharmacists was also conducted to better understand nonpharmacologic interventions to manage patient-felt AEs and support patients receiving abemaciclib.

FINDINGS: The most common AEs across all MONARCH trials were diarrhea, fatigue, nausea, and neutropenia; most events were grade 1-2. Of 282 survey respondents, more than 90% recommended nonpharmacologic interventions to manage AEs.